Neuralstem announces publication of phase 1 trial results of NSI-566
Category: #health  By Paroma Bhattacharya  Date: 2019-07-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Neuralstem announces publication of phase 1 trial results of NSI-566

Subjects were provided immunosuppressive drugs for 28 days after transplantation and were observed for up to 24 months following surgery.

The biopharmaceutical company Neuralstem, Inc. has reportedly announced that it has published a manuscript in Stem Cells Translational Medicine. Apparently, it describes the outcomes of an open label phase 1 clinical study assessing the safety and feasibility of transplantation of its key stem cell asset, NSI-566, for the treatment motor deficits that occur due to ischemic stroke. 

Sources claim that the manuscript summarizes the outcomes of an open label study which was executed at BaYi Brain Hospital, Beijing, China, with Professor Xu Ruxiang. All the nine subjects in the trial had endured chronic motor deficits due to an ischemic stroke 5-24 months before the enrollment. The patients were parted into three groups taking intracerebral injections of NSI-566 cells summing up to 12, 24, or 72 million cells.

Apparently, subjects were provided immunosuppressive drugs for 28 days after transplantation and were observed for up to 24 months following surgery. The therapy was well endured at all dosages and patients showed stable growths in Fugl-Meyer Motor Scores from starting point. This apparently indicates that the procedure is safe and may have potential to offer benefit to patients enduring motor deficits from stroke.

Dr. Ken Carter, Executive Chairman, Neuralstem, reportedly stated that the company has been grateful to the partners at BaYi Brain Hospital and to the subjects who participated in the trial. Although it was a small feasibility trial, the company has been encouraged by the safety profile of the procedure, which has led it to initiate a placebo-controlled study at the same site in September 2018.

For the record, ischemic stroke is the most common type of stroke which occurs due to a hindrance within a blood vessel delivering blood to the brain. Around 15 million individuals globally suffer stroke, out of which nearly 87 percent are ischemic strokes. Post-stroke motor shortfalls include paralysis in legs and arms and can be permanent.

Source credit: https://www.neuralstem.com/news-media/press-releases/detail/264/neuralstem-announces-publication-of-results-from-phase-1



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...